These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 8232363)

  • 1. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease.
    Hauser RA; Olanow CW
    Mov Disord; 1993 Oct; 8(4):512-4. PubMed ID: 8232363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
    Prashantha DK; Pal PK
    Parkinsonism Relat Disord; 2009 Nov; 15(9):718-9. PubMed ID: 19157953
    [No Abstract]   [Full Text] [Related]  

  • 3. How to achieve maximum benefit for the patient with Parkinson's disease.
    Greer M
    Geriatrics; 1976 Apr; 31(4):89-96. PubMed ID: 4356
    [No Abstract]   [Full Text] [Related]  

  • 4. The drug treatment of Parkinson's disease.
    Morris JG
    Aust Fam Physician; 1984 May; 13(5 Suppl):6-8, 11. PubMed ID: 6497767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of neurologic disorders in the elderly.
    Mancall EL; Covington TR; Alonso RJ
    Hosp Pract (Off Ed); 1984 Oct; 19(10):106E, 106I, 106L passim. PubMed ID: 6434551
    [No Abstract]   [Full Text] [Related]  

  • 6. Mental impairment in Parkinson's disease. The role of anticholinergic drugs.
    Meco G; Casacchia M; Lazzari R; Franzese A; Castellana F; Carta A; Iannuccelli M; Agnoli A
    Acta Psychiatr Belg; 1984; 84(4):325-35. PubMed ID: 6507124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dyskinesia induced by anticholinergic drugs--electrophysiological analysis].
    Mano T
    Rinsho Shinkeigaku; 1974 Mar; 14(3):255-65. PubMed ID: 4153837
    [No Abstract]   [Full Text] [Related]  

  • 8. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticholinergics and dyskinesia.
    Linazasoro G
    Mov Disord; 1994 Nov; 9(6):689. PubMed ID: 7845412
    [No Abstract]   [Full Text] [Related]  

  • 10. [Neurological aspects and modern trends in therapy of Parkinson's disease].
    Pavoncello S; Di Bianco V; Di Castro A; Caviglia A; Cellitti M
    Clin Ter; 1980 Feb; 92(4):433-8. PubMed ID: 7449321
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tactile hallucinations induced by trihexyphenidyl in a patient with Parkinson's disease].
    Funakawa I; Jinnai K
    Rinsho Shinkeigaku; 2005 Feb; 45(2):125-7. PubMed ID: 15782612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW; Gracies JM; Goetz CG; Stoessl AJ; Freeman T; Kordower JH; Godbold J; Obeso JA
    Mov Disord; 2009 Feb; 24(3):336-43. PubMed ID: 19006186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease.
    Horrocks PM; Vicary DJ; Rees JE; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1973 Dec; 36(6):936-41. PubMed ID: 4772727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anticholinergics and levodopa in Parkinson's disease: an unnecessary combination in patients treated for the 1st time].
    Giménez-Roldán S; Mateo D; Gil Núñez A
    Rev Clin Esp; 1980 Dec; 159(6):403-7. PubMed ID: 7221107
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A clinical analysis of L-dopa induced dyskinesia treated by posteroventral pallidotomy for Parkinson's disease].
    Zhao G; Li Y; Shao M; Ding Y
    Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):482-4. PubMed ID: 11829894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
    Hirayama K; Uono M; Nakanishi T; Kato N; Nagao Y
    Shinkei Kenkyu No Shimpo; 1971; 15(1):267-85. PubMed ID: 4937721
    [No Abstract]   [Full Text] [Related]  

  • 19. Problems with long-term levodopa therapy for Parkinson's disease.
    Marsden CD
    Clin Neuropharmacol; 1994; 17 Suppl 2():S32-44. PubMed ID: 9358193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.